Eli Lilly and Company $LLY Shares Purchased by DAVENPORT & Co LLC

DAVENPORT & Co LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 11.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 37,891 shares of the company’s stock after buying an additional 3,753 shares during the quarter. DAVENPORT & Co LLC’s holdings in Eli Lilly and Company were worth $40,733,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of LLY. Miller Global Investments LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $33,000. Sumitomo Mitsui Financial Group Inc. acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $27,000. Vermillion & White Wealth Management Group LLC raised its stake in Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares during the period. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth $29,000. Finally, Steph & Co. raised its holdings in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 earnings and revenue momentum — Coverage highlights Eli Lilly’s strong Q4 results and robust GLP‑1 sales that are driving top‑line and margin strength, supporting the company’s growth story. Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way
• Positive Sentiment: Bullish long‑term thesis on GLP‑1 leadership — Retail/bullish analysis argues that Lilly’s leadership in obesity/GLP‑1 drugs makes it a durable growth compounder, reinforcing investor enthusiasm. Could Buying Eli Lilly Today Set You Up for Life?
• Positive Sentiment: Analyst model tweak — Erste Group slightly raised FY‑2026 EPS expectations for LLY (minor lift to forecasts), which supports consensus that Lilly’s earnings power is rising. MarketBeat: Eli Lilly analyst note
• Neutral Sentiment: Media/celebrity endorsement and market performance — Jim Cramer and other outlets are naming Lilly among top healthcare picks, and recent trading showed short‑term outperformance, which can attract flows but also create volatility. Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
• Neutral Sentiment: Industry comparisons and valuation debate — Analyst pieces compare LLY with peers (Novo Nordisk, ABBV), highlighting strong growth but also elevated multiples — important context for investors weighing upside vs. valuation risk. LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?
• Neutral Sentiment: Investor letters and fund commentary reiterate GLP‑1 as the growth engine, but also note concentration risk (revenue tied to a few franchises). Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises Drugs
• Negative Sentiment: Policy/reputation risk around GLP‑1s — Coverage raising the “societal obligation” and broader public debate about GLP‑1s can translate into regulatory scrutiny or reimbursement pressure, a potential near‑term headwind for sentiment. Eli Lilly and the ‘societal obligation’ of GLP-1s

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Argus raised their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Guggenheim lifted their target price on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Royal Bank Of Canada began coverage on shares of Eli Lilly and Company in a research report on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price target for the company. Finally, Bank of America lowered their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a report on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,221.44.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $898.68 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a market cap of $849.09 billion, a PE ratio of 39.16, a price-to-earnings-growth ratio of 1.06 and a beta of 0.40. The business has a 50 day moving average price of $1,010.46 and a two-hundred day moving average price of $960.96.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.